• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.精神分裂症的缓解:5年后的效度、频率、预测因素及患者视角
Dialogues Clin Neurosci. 2010;12(3):393-407. doi: 10.31887/DCNS.2010.12.3/mlambert.
2
The concurrent and predictive validity of symptomatic remission criteria in first-episode schizophrenia.首发精神分裂症症状缓解标准的同时效度和预测效度。
Schizophr Res. 2013 Jan;143(1):107-15. doi: 10.1016/j.schres.2012.10.016. Epub 2012 Nov 11.
3
Remission criteria and functional outcome in patients with schizophrenia, a longitudinal study.精神分裂症患者的缓解标准与功能结局:一项纵向研究
Aust N Z J Psychiatry. 2015 Mar;49(3):266-74. doi: 10.1177/0004867414557680. Epub 2014 Nov 18.
4
Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study.精神分裂症持续症状缓解:来自一项为期两年的前瞻性研究的过程和预测因素。
Schizophr Res. 2022 Jan;239:34-41. doi: 10.1016/j.schres.2021.11.023. Epub 2021 Nov 25.
5
Changes in memory performance over a 12-month period in relation to achieving symptomatic remission after a first-episode psychosis.首次发作精神病后12个月内记忆表现的变化与症状缓解的关系。
Schizophr Res. 2014 Mar;153(1-3):103-8. doi: 10.1016/j.schres.2014.01.024. Epub 2014 Feb 7.
6
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.使用阿立哌唑或氟哌啶醇治疗长达52周的精神分裂症患者的症状缓解情况。
Schizophr Res. 2007 Sep;95(1-3):143-50. doi: 10.1016/j.schres.2007.05.009. Epub 2007 Jul 17.
7
Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study.精神分裂症门诊患者的症状缓解及社会/职业功能:一项横断面研究中的患病率及相关性
Eur Psychiatry. 2007 Nov;22(8):490-8. doi: 10.1016/j.eurpsy.2007.06.005. Epub 2007 Sep 27.
8
Psychometric and clinical evaluation of schizophrenia remission criteria in outpatients with psychotic disorders.精神障碍门诊患者精神分裂症缓解标准的心理计量学和临床评估。
BMC Psychiatry. 2023 Mar 28;23(1):207. doi: 10.1186/s12888-023-04701-3.
9
Remission in schizophrenia: results from a 1-year follow-up observational study.精神分裂症的缓解:一项为期1年的随访观察性研究结果
Schizophr Res. 2009 Mar;108(1-3):214-22. doi: 10.1016/j.schres.2008.12.004. Epub 2009 Jan 24.
10
Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.精神分裂症和重度抑郁症缓解与康复标准的有效性:两项为期一年的随访自然主义研究结果比较。
Eur Arch Psychiatry Clin Neurosci. 2017 Jun;267(4):303-313. doi: 10.1007/s00406-016-0741-2. Epub 2016 Oct 26.

引用本文的文献

1
Two-Injection Start Regimen of Long-Acting Injectable Aripiprazole: Retrospective Data From a Tertiary Care Hospital in Turkey.长效注射用阿立哌唑的两针起始治疗方案:来自土耳其一家三级护理医院的回顾性数据。
Alpha Psychiatry. 2025 Jun 26;26(3):44278. doi: 10.31083/AP44278. eCollection 2025 Jun.
2
Development of Schizophrenia in an Autistic Patient With a Rare Chromosome 8p23.1 Deletion.一名患有罕见8号染色体p23.1缺失的自闭症患者患精神分裂症的病例
Cureus. 2025 May 29;17(5):e85045. doi: 10.7759/cureus.85045. eCollection 2025 May.
3
Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis.使用棕榈酸帕利哌酮每月一次治疗精神分裂症的长期症状缓解和功能改善:一项为期3年的事后分析
Neuropsychiatr Dis Treat. 2025 Jun 18;21:1203-1214. doi: 10.2147/NDT.S523687. eCollection 2025.
4
Predictors of long-term outcome of patients with schizophrenia in Africa: systematic review and meta-analysis.非洲精神分裂症患者长期预后的预测因素:系统评价与荟萃分析
BMC Public Health. 2025 Feb 28;25(1):814. doi: 10.1186/s12889-025-22095-7.
5
Accuracy of machine learning methods in predicting prognosis of patients with psychotic spectrum disorders: a systematic review.机器学习方法预测精神分裂症谱系障碍患者预后的准确性:一项系统评价
BMJ Open. 2025 Feb 25;15(2):e084463. doi: 10.1136/bmjopen-2024-084463.
6
Predicting antipsychotic responsiveness using a machine learning classifier trained on plasma levels of inflammatory markers in schizophrenia.使用基于精神分裂症炎症标志物血浆水平训练的机器学习分类器预测抗精神病药物反应性。
Transl Psychiatry. 2025 Feb 14;15(1):51. doi: 10.1038/s41398-025-03264-z.
7
Exploring the role of TNF-α, TGF-β, and IL-6 serum levels in categorical and noncategorical models of mood and psychosis.探讨 TNF-α、TGF-β 和 IL-6 血清水平在情绪和精神病的分类和非分类模型中的作用。
Sci Rep. 2024 Oct 4;14(1):23117. doi: 10.1038/s41598-024-73937-0.
8
Psychosis Prognosis Predictor: A continuous and uncertainty-aware prediction of treatment outcome in first-episode psychosis.精神病预后预测器:对首发精神病治疗结果的连续且感知不确定性的预测。
Acta Psychiatr Scand. 2025 Mar;151(3):280-292. doi: 10.1111/acps.13754. Epub 2024 Sep 18.
9
Factors associated with health-related quality of life in long-stay inpatients with chronic schizophrenia.长期住院慢性精神分裂症患者健康相关生活质量的相关因素。
PCN Rep. 2022 Sep 8;1(3):e42. doi: 10.1002/pcn5.42. eCollection 2022 Sep.
10
Navigating personal recovery: multinomial logistic regression analysis of schizophrenia outcomes in community-dwelling individuals.探索个人康复:对社区居住个体精神分裂症结局的多项逻辑回归分析
Gen Psychiatr. 2024 Mar 18;37(2):e101325. doi: 10.1136/gpsych-2023-101325. eCollection 2024.

本文引用的文献

1
Remission as perceived by people with schizophrenia, family members and psychiatrists.精神分裂症患者、家庭成员和精神科医生感知的缓解。
Eur Psychiatry. 2012 Aug;27(6):426-31. doi: 10.1016/j.eurpsy.2011.01.013. Epub 2011 May 14.
2
Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort.服务中断率及其预测因素:一项流行病学首发精神病队列研究。
Schizophr Res. 2010 May;118(1-3):256-63. doi: 10.1016/j.schres.2010.01.032. Epub 2010 Mar 4.
3
Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.在精神分裂症中实现缓解和良好的临床功能:长期利培酮长效注射治疗最佳结局的预测因素。
Eur Psychiatry. 2010 May;25(4):220-9. doi: 10.1016/j.eurpsy.2009.09.001. Epub 2009 Nov 18.
4
Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.在 528 名患有精神分裂症且严重受损的患者中,使用氨磺必利治疗,早期和延迟的抗精神病反应与结局预测。
Pharmacopsychiatry. 2009 Nov;42(6):277-83. doi: 10.1055/s-0029-1234105. Epub 2009 Nov 18.
5
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).抗精神病药治疗首发精神分裂症和分裂情感障碍的反应和缓解效果:一项开放随机临床试验(EUFEST)。
Schizophr Res. 2009 Dec;115(2-3):97-103. doi: 10.1016/j.schres.2009.09.019. Epub 2009 Oct 9.
6
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.精神分裂症的缓解:对精神分裂症或分裂情感性障碍患者使用利培酮长效注射剂(RLAI)的意大利为期一年的前瞻性研究。
Hum Psychopharmacol. 2009 Oct;24(7):574-83. doi: 10.1002/hup.1067.
7
Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission.精神分裂症的康复:对症状缓解患者进行的为期1年的随访观察研究结果
Schizophr Res. 2009 Nov;115(1):58-66. doi: 10.1016/j.schres.2009.07.003. Epub 2009 Sep 2.
8
Schizophrenia.精神分裂症
Lancet. 2009 Aug 22;374(9690):635-45. doi: 10.1016/S0140-6736(09)60995-8.
9
The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study.精神分裂症横断面缓解对长期预后的重要性:一项临床前瞻性研究。
Schizophr Res. 2009 Nov;115(1):67-73. doi: 10.1016/j.schres.2009.07.004. Epub 2009 Aug 8.
10
Remission in schizophrenia: analysis in a naturalistic setting.精神分裂症的缓解:自然环境下的分析
Compr Psychiatry. 2009 May-Jun;50(3):200-8. doi: 10.1016/j.comppsych.2008.08.010. Epub 2008 Oct 28.

精神分裂症的缓解:5年后的效度、频率、预测因素及患者视角

Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

作者信息

Lambert Martin, Karow Anne, Leucht Stefan, Schimmelmann Benno G, Naber Dieter

机构信息

Psychosis Centre, Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, German.

出版信息

Dialogues Clin Neurosci. 2010;12(3):393-407. doi: 10.31887/DCNS.2010.12.3/mlambert.

DOI:10.31887/DCNS.2010.12.3/mlambert
PMID:20954433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3181974/
Abstract

In March 2005, the Remission in Schizophrenia Working Group (RSWG) proposed a consensus definition of symptomatic remission in schizophrenia and developed specific operational criteria for its assessment. They pointed out, however, that the validity and the relationship to other outcome dimensions required further examination. This article reviews studies on the validity, frequency, and predictors of symptomatic remission in schizophrenia and studies on patients' perspectives. These studies have demonstrated that the RSWG remission criteria appear achievable and sustainable for a significant proportion of patients, and are related to a better overall symptomatic status and functional outcome and, to a less clear extent, to a better quality of life and cognitive performance. However, achieving symptomatic remission is not automatically concurrent with an adequate status in other outcome dimensions. The results of the present review suggest that the RSWG remission criteria are valid and useful. As such, they should be consistently applied in clinical trials. However the lack of consensus definitions of functional remission and adequate quality of life hampers research on their predictive validity on these outcome dimensions. Future research should therefore search for criteria of these dimensions and test whether the RSWG remission criteria consistently predict a "good" outcome with respect to functioning and quality of life.

摘要

2005年3月,精神分裂症缓解工作组(RSWG)提出了精神分裂症症状缓解的共识定义,并制定了评估其的具体操作标准。然而,他们指出,其有效性以及与其他结局维度的关系需要进一步研究。本文回顾了关于精神分裂症症状缓解的有效性、频率和预测因素的研究以及患者观点的研究。这些研究表明,RSWG缓解标准对相当一部分患者来说似乎是可以实现和维持的,并且与更好的总体症状状态和功能结局相关,在不太明确的程度上,还与更好的生活质量和认知表现相关。然而,实现症状缓解并不自动意味着在其他结局维度上也有足够的状态。本综述结果表明,RSWG缓解标准是有效且有用的。因此,它们应在临床试验中持续应用。然而,功能缓解和足够生活质量缺乏共识定义阻碍了对其在这些结局维度上预测有效性的研究。因此,未来的研究应该寻找这些维度的标准,并测试RSWG缓解标准是否始终能预测功能和生活质量方面的“良好”结局。